Life sciences firm Elysium Health has initiated a clinical trial at Duke Clinical Research Institute to study correlations between epigenetic age and circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults.

Elysium Health’s will calculate biological age in adults using Algorithmic Platform for Epigenetic Examination (APEX), which is an advanced epigenetic platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has been developed by the company to support the 2019 launch of its at-home epigenetic test Index.

The biological age applications, such as DNAm PhenoAge, which have been published, looks at hundreds of sites on the genome in order to ensure high accuracy at the individual level.

A major consideration for developing the methodology which serves as the basis for APEX and Index was the need for refining the technology so as to address the inherent variability of earlier biogenetic age predictors.

The data supporting this methodology will be published later this year by Elysium Health.

It has been demonstrated that Index would be a better predictor of biological age when compared to previous measures.

Glenn Center Biology of Aging Research chief scientist and director Leonard Guarente said: “Over the past decade, epigenetic tests have evolved to measure biological age with an increasing level of accuracy.

“Having studied ageing for more than 30 years, it’s my belief that the field is at a tipping point. The newfound ability to measure biological age allows us to study whether interventions can have an impact, thus unlocking the potential to realise the benefits of aging research in our lifetime.”

This clinical trial is intended to study the correlations to advance the understanding of the links between NAD+ levels, as well as other markers of biological age.

Elysium Health in a statement said: “In the study, NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation will be measured and compared in age-matched individuals to determine whether NAD+ levels are associated with biological age.”

A total of 170 healthy adults between 25 to 80 years of age will be participating in the study, which is expected to complete in May.